Cargando…
Any individual with multiple sclerosis who markedly improves neurologically with high-doses of biotin should be evaluated for biotinidase deficiency
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227140/ https://www.ncbi.nlm.nih.gov/pubmed/32440355 http://dx.doi.org/10.1177/2055217320923131 |
| _version_ | 1783534439963295744 |
|---|---|
| author | Wolf, Barry |
| author_facet | Wolf, Barry |
| author_sort | Wolf, Barry |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7227140 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72271402020-05-21 Any individual with multiple sclerosis who markedly improves neurologically with high-doses of biotin should be evaluated for biotinidase deficiency Wolf, Barry Mult Scler J Exp Transl Clin Letter to the Editor SAGE Publications 2020-04-29 /pmc/articles/PMC7227140/ /pubmed/32440355 http://dx.doi.org/10.1177/2055217320923131 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Letter to the Editor Wolf, Barry Any individual with multiple sclerosis who markedly improves neurologically with high-doses of biotin should be evaluated for biotinidase deficiency |
| title | Any individual with multiple sclerosis who markedly improves neurologically with high-doses of biotin should be evaluated for biotinidase deficiency |
| title_full | Any individual with multiple sclerosis who markedly improves neurologically with high-doses of biotin should be evaluated for biotinidase deficiency |
| title_fullStr | Any individual with multiple sclerosis who markedly improves neurologically with high-doses of biotin should be evaluated for biotinidase deficiency |
| title_full_unstemmed | Any individual with multiple sclerosis who markedly improves neurologically with high-doses of biotin should be evaluated for biotinidase deficiency |
| title_short | Any individual with multiple sclerosis who markedly improves neurologically with high-doses of biotin should be evaluated for biotinidase deficiency |
| title_sort | any individual with multiple sclerosis who markedly improves neurologically with high-doses of biotin should be evaluated for biotinidase deficiency |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227140/ https://www.ncbi.nlm.nih.gov/pubmed/32440355 http://dx.doi.org/10.1177/2055217320923131 |
| work_keys_str_mv | AT wolfbarry anyindividualwithmultiplesclerosiswhomarkedlyimprovesneurologicallywithhighdosesofbiotinshouldbeevaluatedforbiotinidasedeficiency |